JPWO2020043152A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020043152A5 JPWO2020043152A5 JP2021510019A JP2021510019A JPWO2020043152A5 JP WO2020043152 A5 JPWO2020043152 A5 JP WO2020043152A5 JP 2021510019 A JP2021510019 A JP 2021510019A JP 2021510019 A JP2021510019 A JP 2021510019A JP WO2020043152 A5 JPWO2020043152 A5 JP WO2020043152A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- isolated polynucleotide
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000023 polynucleotide Polymers 0.000 claims 19
- 239000002157 polynucleotide Substances 0.000 claims 19
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 102000004965 antibodies Human genes 0.000 claims 11
- 108090001123 antibodies Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 102000038129 antigens Human genes 0.000 claims 11
- 108091007172 antigens Proteins 0.000 claims 11
- 108010060374 FSH Receptors Proteins 0.000 claims 7
- 102000018343 Follicle stimulating hormone receptor Human genes 0.000 claims 7
- 229920001184 polypeptide Polymers 0.000 claims 7
- 210000002865 immune cell Anatomy 0.000 claims 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 5
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037240 fusion proteins Human genes 0.000 claims 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 210000001185 Bone Marrow Anatomy 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 210000000581 Natural Killer T-Cells Anatomy 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 102000003735 mesothelin Human genes 0.000 claims 1
- 108090000015 mesothelin Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001568 sexual Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018103050 | 2018-08-29 | ||
| CNPCT/CN2018/103050 | 2018-08-29 | ||
| CNPCT/CN2019/083918 | 2019-04-23 | ||
| CN2019083918 | 2019-04-23 | ||
| PCT/CN2019/103215 WO2020043152A1 (fr) | 2018-08-29 | 2019-08-29 | Constructions de récepteur d'antigène chimère (car) anti-mésothéline et ses utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534762A JP2021534762A (ja) | 2021-12-16 |
| JPWO2020043152A5 true JPWO2020043152A5 (fr) | 2022-09-01 |
| JP7490915B2 JP7490915B2 (ja) | 2024-05-28 |
Family
ID=69643948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510019A Active JP7490915B2 (ja) | 2018-08-29 | 2019-08-29 | 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11932698B2 (fr) |
| EP (1) | EP3844282A4 (fr) |
| JP (1) | JP7490915B2 (fr) |
| KR (1) | KR20210053318A (fr) |
| CN (1) | CN112639102B (fr) |
| AU (1) | AU2019327913A1 (fr) |
| CA (1) | CA3111087A1 (fr) |
| IL (1) | IL281098A (fr) |
| SG (1) | SG11202101773WA (fr) |
| TW (1) | TW202024330A (fr) |
| WO (1) | WO2020043152A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3298033T4 (fi) | 2015-05-18 | 2023-09-22 | Tcr2 Therapeutics Inc | Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille |
| EP3573464A4 (fr) * | 2017-01-26 | 2020-12-30 | Sangamo Therapeutics, Inc. | Ingénierie de cellules b |
| WO2021226289A2 (fr) * | 2020-05-05 | 2021-11-11 | TCR2 Therapeutics Inc. | Compositions et procédés pour la reprogrammation de tcr au moyen de protéines de fusion spécifiques cd70 |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| AU2021245153B2 (en) * | 2020-08-04 | 2022-06-30 | Cellengene Inc | Anti-mesothelin chimeric antigen receptor specifically binding to mesothelin |
| GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
| WO2022037562A1 (fr) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Cellules immunoréactives modifiées et leurs utilisations |
| WO2022232277A1 (fr) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS DE REPROGRAMMATION TCR À L'AIDE DE PROTÉINES DE FUSION ET DE COMMUTATION TGFβR |
| JP7487989B2 (ja) * | 2021-05-26 | 2024-05-21 | セレンジーン インコーポレイテッド | 抗メソテリンｓｃＦｖを含むキメリック抗原受容体及びその用途 |
| WO2022257984A1 (fr) * | 2021-06-08 | 2022-12-15 | 南京驯鹿医疗技术有限公司 | Préparation pour cellules à récepteur antigénique chimérique (car) améliorées et leur utilisation |
| WO2023020472A1 (fr) * | 2021-08-16 | 2023-02-23 | Utc Therapeutics (Shanghai) Co., Ltd. | Anticorps ciblant la mésothéline et leurs utilisations dans des thérapies anticancéreuses |
| TW202323281A (zh) * | 2021-10-14 | 2023-06-16 | 美商泰尼歐生物公司 | 間皮素結合蛋白及其用途 |
| WO2023070126A1 (fr) * | 2021-10-22 | 2023-04-27 | Regents Of The University Of Minnesota | Récepteurs de lymphocytes t génétiquement modifiés |
| CN114560949B (zh) * | 2022-03-07 | 2023-09-26 | 中国人民解放军空军军医大学 | 一种具有增强car-t细胞抗肿瘤能力的嵌合抗原受体、d-car-t细胞及其应用 |
| WO2024088371A1 (fr) * | 2022-10-28 | 2024-05-02 | 原启生物科技(上海)有限责任公司 | Protéine de liaison à l'antigène ciblant msln |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405053B2 (en) * | 2003-05-20 | 2008-07-29 | The University Court Of The University Of Glasgow | Materials and methods relating to G-protein coupled receptor oligomers |
| WO2014004549A2 (fr) * | 2012-06-27 | 2014-01-03 | Amgen Inc. | Protéines de liaison anti-mésothéline |
| JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
| CN102875685B (zh) * | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| ES2928000T3 (es) | 2014-06-06 | 2022-11-14 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
| AU2015317608B2 (en) * | 2014-09-17 | 2021-03-11 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| ES2904573T3 (es) * | 2015-03-27 | 2022-04-05 | Univ Southern California | Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos |
| CN104877032B (zh) | 2015-06-26 | 2018-12-11 | 中国医学科学院血液病医院（血液学研究所） | Cd33特异性嵌合抗原受体及其应用 |
| JP2020500530A (ja) * | 2016-12-02 | 2020-01-16 | ユニバーシティ オブ サザン カリフォルニア | 合成免疫受容体およびその使用方法 |
| CN110494451B (zh) | 2017-01-13 | 2023-12-01 | 塞尔达拉医疗有限责任公司 | 靶向tim-1的嵌合抗原受体 |
-
2019
- 2019-08-29 AU AU2019327913A patent/AU2019327913A1/en active Pending
- 2019-08-29 TW TW108131105A patent/TW202024330A/zh unknown
- 2019-08-29 SG SG11202101773WA patent/SG11202101773WA/en unknown
- 2019-08-29 CN CN201980055889.4A patent/CN112639102B/zh active Active
- 2019-08-29 CA CA3111087A patent/CA3111087A1/fr active Pending
- 2019-08-29 KR KR1020217009330A patent/KR20210053318A/ko unknown
- 2019-08-29 EP EP19854280.5A patent/EP3844282A4/fr active Pending
- 2019-08-29 WO PCT/CN2019/103215 patent/WO2020043152A1/fr unknown
- 2019-08-29 US US17/270,970 patent/US11932698B2/en active Active
- 2019-08-29 JP JP2021510019A patent/JP7490915B2/ja active Active
-
2021
- 2021-02-24 IL IL281098A patent/IL281098A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107151269B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
| CN102369214B (zh) | 三价、双特异性抗体 | |
| RU2598248C2 (ru) | Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab | |
| CN103068846B (zh) | 包含二硫键稳定性Fv片段的双特异性抗体 | |
| JPWO2020043152A5 (fr) | ||
| WO2021058000A1 (fr) | Anticorps anti-claudine 18,2 humaine et son application | |
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| JP2011157397A5 (fr) | ||
| WO2019196309A1 (fr) | Anticorps anti-pd-l1 et son utilisation | |
| WO2018176992A1 (fr) | Nouveau type d'anticorps bispécifique et son utilisation | |
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| CN112105391B (zh) | 抗-bcma抗体及其用途 | |
| WO2022188801A1 (fr) | Protéine de liaison à pd-1 et son utilisation pharmaceutique | |
| CN115151572B (zh) | 针对ror1的抗体及其用途 | |
| US20230357398A1 (en) | Novel human antibodies binding to human cd3 epsilon | |
| WO2022127066A1 (fr) | Anticorps bispécifique pour neutraliser de manière spécifique un signal tgf-β de lymphocytes t auxiliaires, combinaison pharmaceutique et utilisation associées | |
| JP2020502233A5 (fr) | ||
| CN113637075A (zh) | 双特异性抗原结合分子及其医药用途 | |
| CA2978902A1 (fr) | Anticorps therapeutiques se fixant a jag1 | |
| JPWO2020218951A5 (fr) | ||
| CN114573704B (zh) | Pd-1/ctla-4结合蛋白及其医药用途 | |
| WO2023241656A1 (fr) | Anticorps bispécifique contenant un anticorps anti-cldn18.2, composition pharmaceutique et utilisation associées | |
| CN117586413A (zh) | 异多聚体蛋白质及其制备方法 | |
| AU2021224787A1 (en) | CD137 binding molecules and uses thereof | |
| TW202241956A (zh) | 新穎抗cd24抗體 |